KR20260011191A - 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료 - Google Patents

오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Info

Publication number
KR20260011191A
KR20260011191A KR1020257043253A KR20257043253A KR20260011191A KR 20260011191 A KR20260011191 A KR 20260011191A KR 1020257043253 A KR1020257043253 A KR 1020257043253A KR 20257043253 A KR20257043253 A KR 20257043253A KR 20260011191 A KR20260011191 A KR 20260011191A
Authority
KR
South Korea
Prior art keywords
olbinutuzumab
cycle
per hour
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257043253A
Other languages
English (en)
Korean (ko)
Inventor
미하엘 벵거
메르다드 모바셔
친-유 린
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20260011191(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20260011191A publication Critical patent/KR20260011191A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020257043253A 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료 Pending KR20260011191A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
US62/574,297 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION
KR1020247035575A KR102906969B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247035575A Division KR102906969B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Publications (1)

Publication Number Publication Date
KR20260011191A true KR20260011191A (ko) 2026-01-22

Family

ID=64362606

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257043253A Pending KR20260011191A (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
KR1020207014191A Active KR102766089B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
KR1020247035575A Active KR102906969B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207014191A Active KR102766089B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
KR1020247035575A Active KR102906969B1 (ko) 2017-10-19 2018-10-19 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Country Status (14)

Country Link
US (2) US12129304B2 (https=)
EP (2) EP3697818B1 (https=)
JP (2) JP6860652B2 (https=)
KR (3) KR20260011191A (https=)
CN (2) CN120983618A (https=)
AU (2) AU2018303836B2 (https=)
BR (1) BR112020007731A2 (https=)
CA (1) CA3079374A1 (https=)
ES (1) ES3005784T3 (https=)
IL (2) IL321935A (https=)
MX (2) MX419643B (https=)
PL (1) PL3697818T3 (https=)
TW (2) TWI805630B (https=)
WO (1) WO2019017499A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6860652B2 (ja) * 2017-10-19 2021-04-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 医薬組成物
AR122307A1 (es) * 2019-10-04 2022-08-31 Chugai Pharmaceutical Co Ltd Agente de supresión de la proliferación celular de cáncer cd20 positivo tolerante a obinutuzumab, y composición farmacéutica, medicamento, fabricación, procedimiento de supresión de la proliferación celular, procedimiento de tratamiento, anticuerpo anti-cd20 de tipo ii, compuesto, sus combinaciones, y agente potenciador y agente inductor, relacionados con estos
CN117941219A (zh) 2021-09-17 2024-04-26 佳能株式会社 送电设备和受电设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
BRPI0820819B1 (pt) * 2007-12-21 2021-06-08 F. Hoffmann-La Roche Ag formulação de anticorpos humanizados b-ly 1 e seu uso
TW201618775A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物
WO2017100722A1 (en) * 2015-12-09 2017-06-15 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US12377681B2 (en) 2017-07-21 2025-08-05 The Yokohama Rubber Co., Ltd. Pneumatic tire
JP6860652B2 (ja) * 2017-10-19 2021-04-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 医薬組成物

Also Published As

Publication number Publication date
TW201922284A (zh) 2019-06-16
TWI828593B (zh) 2024-01-01
US12129304B2 (en) 2024-10-29
CA3079374A1 (en) 2019-01-24
CN111212854A (zh) 2020-05-29
JP6860652B2 (ja) 2021-04-21
MX2024009217A (es) 2024-11-08
JP2019528282A (ja) 2019-10-10
IL273909B2 (en) 2025-12-01
IL321935A (en) 2025-09-01
MX2020003418A (es) 2020-07-20
JP2021152002A (ja) 2021-09-30
TW202342099A (zh) 2023-11-01
WO2019017499A3 (en) 2019-02-21
PL3697818T3 (pl) 2025-03-24
AU2025205481A1 (en) 2025-08-07
CN120983618A (zh) 2025-11-21
KR20240157135A (ko) 2024-10-31
IL273909B1 (en) 2025-08-01
MX419643B (es) 2025-01-14
WO2019017499A2 (en) 2019-01-24
IL273909A (en) 2020-05-31
AU2018303836B2 (en) 2025-04-17
ES3005784T3 (en) 2025-03-17
JP7370357B2 (ja) 2023-10-27
KR102766089B1 (ko) 2025-02-13
KR102906969B1 (ko) 2026-01-05
TWI805630B (zh) 2023-06-21
KR20200067196A (ko) 2020-06-11
AU2018303836A1 (en) 2020-05-14
EP3697818A2 (en) 2020-08-26
EP4520347A2 (en) 2025-03-12
EP3697818B1 (en) 2024-11-27
US20200299398A1 (en) 2020-09-24
US20250026847A1 (en) 2025-01-23
EP4520347A3 (en) 2025-06-04
BR112020007731A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
IL273937B2 (en) Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
JP2025156294A (ja) 皮下投与のための抗ｃｄ３８抗体の製剤
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
CN117769435A (zh) 通过施用抗cd127剂治疗cd127阳性癌症的方法
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
US12599620B2 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
WO2026060367A1 (en) Methods of treating disease using anti-cd94 antibodies
KR20240082393A (ko) 항-갈렉틴-9 항체 및 이의 치료적 용도
BR122025025322A2 (pt) Composição farmacêutica para o tratamento de linfoma de células b e uso do obinutuzumabe

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000